Kazumi Horiguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kazumi Horiguchi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Katsumasa Kuroi
Division of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
6 shared publications- Tomoyuki Aruga
Institute of Science Tokyo
6 shared publications - Toshinari Yamashita
Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
6 shared publications - Hiromi Miyamoto
Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
4 shared publications - Yayoi Honda
Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
4 shared publications Risa Goto
Department of Breast Surgery Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
3 shared publications
Latest Publications
- 1 January 2018
- Published by Japan Association of Breast Cancer Screening in Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening)
- Vol. 27 (2) , 161-165
Evaluation of Stereotactic Vacuum-Assisted Breast Biopsy for Microcalcifications Diagnosed as Category 3
マンモグラフィのカテゴリー3(C-3)石灰化症例におけるステレオガイド下吸引式組織生検(ST-VAB)の結果を検討する。2005年1月から2017年4月に当院で施行したST-VAB 症例のうちC-3の石灰化を有する287症例289病変を後方視的に検討した。 ST-VAB 結果は,良性194例,悪性69例(浸潤癌11例,非浸潤癌58例),良悪性鑑別困難26例であった。良性と悪性では石灰化の形状と分布に差は認められなかった。悪性では55歳以上の割合が高く(χ 二乗検定p=0.02),乳房造影MRI 検査(以下MRI)で造影域を認めた症例が多かった(χ 二乗検定p=0.0001)。ST-VAB で非浸潤癌の診断で手術を施行した55例のうち,術後病理診断で浸潤部を認めた症例は13例(24%)であった。51例でセンチネルリンパ節生検が行われ,すべて転移陰性であった。 55歳以上でMRI 検査において造影所見を有する症例ではST-VAB の適応と考えられる。一方,今回の検討結果から良性が大部分を占めること,悪性であっても非浸潤癌が80%であることが明らかとなった。閉経前でMRI でも造影所見を認めない症例では,即時にST-VAB を行わず,経過観察でも妥当性があると思われた。
- 1 January 2018
- Published by Japan Association of Breast Cancer Screening in Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening)
- Vol. 27 (2) , 161-165
Evaluation of Stereotactic Vacuum-Assisted Breast Biopsy for Microcalcifications Diagnosed as Category 3
マンモグラフィのカテゴリー3(C-3)石灰化症例におけるステレオガイド下吸引式組織生検(ST-VAB)の結果を検討する。2005年1月から2017年4月に当院で施行したST-VAB 症例のうちC-3の石灰化を有する287症例289病変を後方視的に検討した。 ST-VAB 結果は,良性194例,悪性69例(浸潤癌11例,非浸潤癌58例),良悪性鑑別困難26例であった。良性と悪性では石灰化の形状と分布に差は認められなかった。悪性では55歳以上の割合が高く(χ 二乗検定p=0.02),乳房造影MRI 検査(以下MRI)で造影域を認めた症例が多かった(χ 二乗検定p=0.0001)。ST-VAB で非浸潤癌の診断で手術を施行した55例のうち,術後病理診断で浸潤部を認めた症例は13例(24%)であった。51例でセンチネルリンパ節生検が行われ,すべて転移陰性であった。 55歳以上でMRI 検査において造影所見を有する症例ではST-VAB の適応と考えられる。一方,今回の検討結果から良性が大部分を占めること,悪性であっても非浸潤癌が80%であることが明らかとなった。閉経前でMRI でも造影所見を認めない症例では,即時にST-VAB を行わず,経過観察でも妥当性があると思われた。
- Open Access
- 26 January 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 46
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
- 26 January 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 46
Open AccessInvasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
- Open Access
- 1 January 2016
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 77 (8) , 1896-1901
A Breast Cancer Patient with Long-term Survival Developing Post-operative Carcinomatous Pleuritis—A Case Report—
- 1 January 2016
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 77 (8) , 1896-1901
Open AccessA Breast Cancer Patient with Long-term Survival Developing Post-operative Carcinomatous Pleuritis—A Case Report—
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii142
Clinical outcome for HR + /HER2- stage IV breast cancer patients
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii142
Clinical outcome for HR + /HER2- stage IV breast cancer patients
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii103
Management of bone metastasis in the patients achieved 10-year survival with recurrence from breast cancer
Background: According to the progression of treatment for the breast cancer, it has become possible to attain long-term survival in some cases of the metastatic breast cancer patients. We investigated about the patients with bone metastasis achieved long survival in our hospital.
- 30 October 2015
- Published by Elsevier in Annals of Oncology
- Vol. 26, vii103
Management of bone metastasis in the patients achieved 10-year survival with recurrence from breast cancer
Background: According to the progression of treatment for the breast cancer, it has become possible to attain long-term survival in some cases of the metastatic breast cancer patients. We investigated about the patients with bone metastasis achieved long survival in our hospital.
- 1 June 2012
- Vol. 39 (6) , 1013-6
[A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
A 62-year-old woman was diagnosed with primary left breast cancer during a follow-up for an ovarian tumor. She had at first undergone surgical resection of an ovarian tumor, and a pathological examination had revealed ovarian cancer. Gynecologists decided to treat her ovarian cancer with chemotherapy, and we were initially planning to provide treatment for breast cancer after that was completed. Sentinel lymph node biopsy performed before chemotherapy revealed no axillary metastases. The patient received six courses of intravenous PTX (175 mg/m2 on day 1, every 3 weeks) and intravenous CBDCA (AUC6 on day 1, every 3 weeks) as combination therapy. Abdominal lymph node dissection was performed between chemotherapy courses 3 and 4. The lump in the left breast showed partial clinical response, and partial resection of the left breast was performed after completion of chemotherapy. In Japan, few cases of primary breast cancer treated preoperatively using carboplatin-containing regimens have been described.
- 1 June 2012
- Vol. 39 (6) , 1013-6
[A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
A 62-year-old woman was diagnosed with primary left breast cancer during a follow-up for an ovarian tumor. She had at first undergone surgical resection of an ovarian tumor, and a pathological examination had revealed ovarian cancer. Gynecologists decided to treat her ovarian cancer with chemotherapy, and we were initially planning to provide treatment for breast cancer after that was completed. Sentinel lymph node biopsy performed before chemotherapy revealed no axillary metastases. The patient received six courses of intravenous PTX (175 mg/m2 on day 1, every 3 weeks) and intravenous CBDCA (AUC6 on day 1, every 3 weeks) as combination therapy. Abdominal lymph node dissection was performed between chemotherapy courses 3 and 4. The lump in the left breast showed partial clinical response, and partial resection of the left breast was performed after completion of chemotherapy. In Japan, few cases of primary breast cancer treated preoperatively using carboplatin-containing regimens have been described.
- 1 October 2011
- Vol. 38 (10) , 1639-45
[Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
We investigated predictors for axillary node metastasis at breast surgery after neoadjuvant chemotherapy (NAC) in patients with pre-chemotherapy-sentinel node positive breast cancer. Eighty-two patients were diagnosed as having positive sentinel lymph node (SLN), who had axillary lymph node dissection (ALND) performed after combination anthracycline/taxan based NAC, between 2002 and 2009. Eighteen (22.0%) of the 82 patients had residual axillary metastases after NAC. Multivariate analysis revealed that SLNs status before NAC was an important factor in predicting residual axillary metastases. Predictors of residual nodal disease were the number of macrometastases and the percentage (>50%) of positive SLNs in all SLNs. Among a subgroup of hormone-receptor positive and HER2-negative tumors, the risk of residual nodal metastases were high sensitivity of hormone receptor, with more than 50% of tumor cells staining positive for ER and PgR. Patients with two or more positive SLNs before NAC had a high risk of residual nodal metastasis after NAC.
- 1 October 2011
- Vol. 38 (10) , 1639-45
[Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
We investigated predictors for axillary node metastasis at breast surgery after neoadjuvant chemotherapy (NAC) in patients with pre-chemotherapy-sentinel node positive breast cancer. Eighty-two patients were diagnosed as having positive sentinel lymph node (SLN), who had axillary lymph node dissection (ALND) performed after combination anthracycline/taxan based NAC, between 2002 and 2009. Eighteen (22.0%) of the 82 patients had residual axillary metastases after NAC. Multivariate analysis revealed that SLNs status before NAC was an important factor in predicting residual axillary metastases. Predictors of residual nodal disease were the number of macrometastases and the percentage (>50%) of positive SLNs in all SLNs. Among a subgroup of hormone-receptor positive and HER2-negative tumors, the risk of residual nodal metastases were high sensitivity of hormone receptor, with more than 50% of tumor cells staining positive for ER and PgR. Patients with two or more positive SLNs before NAC had a high risk of residual nodal metastasis after NAC.
- 1 June 2010
- Vol. 57 (2) , 155-63
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.
HER2 oncoprotein plays an essential role in breast cancer growth and differentiation. Determination of HER2 status contributes not only to predicting survival but also to selecting the patients for anti-HER2 therapy. HER2 protein expressed in human cancer cells often contains variant forms as well as the full-length wild-type form. In the present study, we investigated the subcellular localization of HER2 protein in 1053 primary breast cancer tissues. HER2 protein was stained by various immunohistochemical methods and studied by immunoelectron microscopy to confirm the intracellular localization. Thirty-four of 1053 specimens showed cytoplasmic staining of the intracellular domain of HER2 protein by the HercepTest and CB-11. In contrast, no immunoreactivity to the antibodies against the extracellular domain was observed. None of the 34 specimens showed amplification of the HER2 protein by fluorescence in situ hybridization. Subsequently, we studied the association of the cytoplasmic expression of HER2 with neuroendocrine differentiation. Interestingly, all 34 specimens had some positive signals of neuroendocrine markers such as synaptophysin, chromogranin A, neuron-specific enolase, and CD56. Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation.
- 1 June 2010
- Vol. 57 (2) , 155-63
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.
HER2 oncoprotein plays an essential role in breast cancer growth and differentiation. Determination of HER2 status contributes not only to predicting survival but also to selecting the patients for anti-HER2 therapy. HER2 protein expressed in human cancer cells often contains variant forms as well as the full-length wild-type form. In the present study, we investigated the subcellular localization of HER2 protein in 1053 primary breast cancer tissues. HER2 protein was stained by various immunohistochemical methods and studied by immunoelectron microscopy to confirm the intracellular localization. Thirty-four of 1053 specimens showed cytoplasmic staining of the intracellular domain of HER2 protein by the HercepTest and CB-11. In contrast, no immunoreactivity to the antibodies against the extracellular domain was observed. None of the 34 specimens showed amplification of the HER2 protein by fluorescence in situ hybridization. Subsequently, we studied the association of the cytoplasmic expression of HER2 with neuroendocrine differentiation. Interestingly, all 34 specimens had some positive signals of neuroendocrine markers such as synaptophysin, chromogranin A, neuron-specific enolase, and CD56. Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation.